Physician profile
Stephen K Milroy
NPI 1588629166
$724.88
in general payments reported to CMS, 2019-2025
12 companies · $64.88 in 2025
The $64.88 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2023: $98.75 · 2025: $64.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $182.91 | 2019 | |
| Dermavant Sciences, INC. | $98.75 | 2023 | Vtama |
| Prugen, INC. Pharmaceuticals | $90.13 | 2019 | |
| Abbvie INC. | $87.86 | 2019 | |
| Pfizer INC. | $76.09 | 2019 | |
| Organon LLC | $39.88 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.98 | 2019 | |
| Mission Pharmacal Company | $32.63 | 2019 | |
| Hill Dermaceuticals, INC. | $25.00 | 2025 | Tolak |
| Leo Pharma INC. | $22.99 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $20.66 | 2019 | |
| Janssen Biotech, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Milroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.